WO2015069922A3 - Alk antibodies, conjugates, and chimeric antigen receptors, and their use - Google Patents

Alk antibodies, conjugates, and chimeric antigen receptors, and their use Download PDF

Info

Publication number
WO2015069922A3
WO2015069922A3 PCT/US2014/064383 US2014064383W WO2015069922A3 WO 2015069922 A3 WO2015069922 A3 WO 2015069922A3 US 2014064383 W US2014064383 W US 2014064383W WO 2015069922 A3 WO2015069922 A3 WO 2015069922A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
antigen receptors
disclosed
conjugates
antibodies
Prior art date
Application number
PCT/US2014/064383
Other languages
French (fr)
Other versions
WO2015069922A2 (en
Inventor
Rimas ORENTAS
Crystal Mackall
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361900806P priority Critical
Priority to US61/900,806 priority
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2015069922A2 publication Critical patent/WO2015069922A2/en
Publication of WO2015069922A3 publication Critical patent/WO2015069922A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Chimeric antigen receptors that specifically bind to anaplastic lymphoma kinase are disclosed. Nucleic acids, recombinant expression vectors, host cells, antibodies, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
PCT/US2014/064383 2013-11-06 2014-11-06 Alk antibodies, conjugates, and chimeric antigen receptors, and their use WO2015069922A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361900806P true 2013-11-06 2013-11-06
US61/900,806 2013-11-06

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14805427.3A EP3066118B1 (en) 2013-11-06 2014-11-06 Alk antibodies, conjugates, and chimeric antigen receptors, and their use
US15/034,171 US20160280798A1 (en) 2013-11-06 2014-11-06 Alk antibodies, conjugates, and chimeric antigen receptors, and their use

Publications (2)

Publication Number Publication Date
WO2015069922A2 WO2015069922A2 (en) 2015-05-14
WO2015069922A3 true WO2015069922A3 (en) 2015-09-03

Family

ID=51999535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/064383 WO2015069922A2 (en) 2013-11-06 2014-11-06 Alk antibodies, conjugates, and chimeric antigen receptors, and their use

Country Status (3)

Country Link
US (1) US20160280798A1 (en)
EP (1) EP3066118B1 (en)
WO (1) WO2015069922A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
DK3313874T3 (en) 2015-06-26 2021-05-03 Univ Southern California MASKING OF CHIMARY ANTIGEN RECEPTOR T CELLS FOR TUMOR-SPECIFIC ACTIVATION
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
PL240585B1 (en) 2016-07-18 2022-05-02 Helix Biopharma Corp Immunological CAR cells for treatment of tumours
GB201721421D0 (en) * 2017-12-20 2018-01-31 Ucl Business Plc Chimeric antigen receptor
CA3113896A1 (en) 2018-09-27 2020-04-02 Autolus Limited Chimeric antigen receptor
WO2020241827A1 (en) 2019-05-31 2020-12-03 キッセイ薬品工業株式会社 Chimeric antigen receptor-expressing cells targeting alk
WO2021155016A1 (en) * 2020-01-28 2021-08-05 The Children's Medical Center Corporation Anaplastic lymphoma kinase chimeric antigen receptors and methods of use
GB202003277D0 (en) * 2020-03-06 2020-04-22 King S College London Therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
JPH0115514B2 (en) 1979-09-21 1989-03-17 Takeda Chemical Industries Ltd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPH0114918B2 (en) 1981-05-20 1989-03-14 Takeda Chemical Industries Ltd
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
FI102355B1 (en) 1988-02-11 1998-11-30 Squibb Bristol Myers Co A method for preparing anthracycline immunoconjugates having a linking spacer
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DE69131449T2 (en) 1990-05-11 1999-11-25 Us Health IMPROVED EXOTOXINS FROM PSEUDOMONAS WITH LOW TOXITY IN ANIMALS AND HIGH CELL-KILLING ACTIVITY
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
PT871490E (en) 1995-12-22 2003-07-31 Squibb Bristol Myers Co BRIDGED HIDRAZONE LIGANTS
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
PT2357006E (en) 2002-07-31 2016-01-22 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ541861A (en) 2003-02-26 2009-05-31 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
GB0415138D0 (en) 2004-07-06 2004-08-11 Martin William J Proximity sensor
JP4242911B2 (en) 2004-08-26 2009-03-25 ファイザー・インク Enantiopure aminoheteroaryl compounds as protein kinase inhibitors
EP1910407B1 (en) 2005-07-29 2011-09-14 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
BRPI0619420A2 (en) 2005-12-05 2011-10-04 Pfizer Prod Inc polymorph-free bases of a c-met / hgfr inhibitor, as well as their use, pharmaceutical composition, capsule and use thereof
PT1959955E (en) 2005-12-05 2011-01-04 Pfizer Prod Inc Method of treating abnormal cell growth
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
US8936792B2 (en) 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
JP2013505944A (en) 2009-09-24 2013-02-21 シアトル ジェネティックス, インコーポレイテッド DR5 ligand drug conjugate
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011106723A2 (en) 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
DK3214091T3 (en) 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
JP6267644B2 (en) 2011-10-20 2018-01-24 アメリカ合衆国 Anti-CD22 chimeric antigen receptor
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALEC WALKER ET AL: "Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. Suppl 3, 6 November 2014 (2014-11-06), pages P40, XP021202601, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-S3-P40 *
LEE D W ET AL: "The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 10, 15 May 2012 (2012-05-15), pages 2780 - 2790, XP002725492, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-1920 *
MAZOT PIERRE ET AL: "Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment", PLOS ONE, vol. 7, no. 3, March 2012 (2012-03-01), XP002736064 *
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 280, no. 28, 1 July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258, DOI: 10.1074/JBC.M501972200 *
ORENTAS, RJ ET AL.: "Designing a New Chimeric Antigen Receptor for the TumorAntigen ALK", vol. 33, no. 8, 1 October 2010 (2010-10-01), pages 905 - 905, XP055169988, Retrieved from the Internet <URL:http://pdfs.journals.lww.com/immunotherapy-journal/2010/10000/Abstracts_for_the_25th_Annual_Scientific_Meeting.13.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1424098503278;payload|mY8D3u1TCCsNvP5E421JYPPlNl9ZUXrQDsjmMHeXqBgfxP56d5BAis WhfSrPR1S6lcHrAT5WTvTkrI7Jc1zUq2UlEn8N1x7qr2heZXbSZE2/LnQ> [retrieved on 20150216] *
RIMAS J ORENTAS ET AL: "ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P27, XP021167231, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P27 *
RIMAS J. ORENTAS ET AL: "Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055127272, DOI: 10.3389/fonc.2012.00194 *
RIMAS J. ORENTAS ET AL: "Immunotherapy Targets in Pediatric Cancer", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055170174, DOI: 10.3389/fonc.2012.00003 *
YAËL P. MOSSÉ ET AL: "Identification of ALK as a major familial neuroblastoma predisposition gene", NATURE, vol. 455, no. 7215, 16 October 2008 (2008-10-16), pages 930 - 935, XP055004093, ISSN: 0028-0836, DOI: 10.1038/nature07261 *

Also Published As

Publication number Publication date
US20160280798A1 (en) 2016-09-29
EP3066118A2 (en) 2016-09-14
WO2015069922A2 (en) 2015-05-14
EP3066118B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
MX2019001294A (en) Chimeric antigen receptors targeting bcma and methods of use thereof.
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
WO2015054691A3 (en) Tem8 antibodies and their use
PH12014502527A1 (en) St2 antigen binding proteins
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
WO2015108998A3 (en) Cartilage targeting agents and their use
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2014005546A (en) Albumin binding antibodies and binding fragments thereof.
MX2015008446A (en) Multivalent binding protein compositions.
WO2012109624A3 (en) Monovalent and multivalent multispecific complexes and uses thereof
UA125252C2 (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
NZ717399A (en) Antibodies against csf-1r
EP3642344A4 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
AU2015347015A8 (en) Antibody drug conjugates
MX2018004503A (en) Anti-cd30 chimeric antigen receptors.
WO2014131019A3 (en) Her-1, her-3 and igf-1r compositions and uses thereof
MX2015014198A (en) Antibodies targeting m-csf.
EP3722313A4 (en) Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
WO2015057461A3 (en) Antibodies that specifically bind ataxia telangiectasia-mutated (atm) and rad3-related kinase phosphorylated
MX2016014726A (en) Her1 antigen binding proteins binding to the beta-hairpin of her1.
WO2015017113A3 (en) Tumor selective antibodies specific to oncofetal antigen / immature laminin receptor protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805427

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15034171

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2014805427

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014805427

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE